ELHAM AMJAD1, RAFFAELE PEZZANI2,3,*, BABAK SOKOUTI1,*
Oncology Research, Vol.32, No.3, pp. 439-461, 2024, DOI:10.32604/or.2023.044473
- 06 February 2024
Abstract Noncoding RNAs instruct the Cas9 nuclease to site-specifically cleave DNA in the CRISPR/Cas9 system. Despite the high incidence of hepatocellular carcinoma (HCC), the patient’s outcome is poor. As a result of the emergence of therapeutic resistance in HCC patients, clinicians have faced difficulties in treating such tumor. In addition, CRISPR/Cas9 screens were used to identify genes that improve the clinical response of HCC patients. It is the objective of this article to summarize the current understanding of the use of the CRISPR/Cas9 system for the treatment of cancer, with a particular emphasis on HCC as… More >